HIV and Oral Health Research Insights

The intersection of HIV infection and oral health represents one of the most significant areas of research in contemporary dentistry and oral medicine. As we continue to advance our understanding of this global health challenge, the oral cavity often serves as an early indicator of HIV progression and immune system deterioration [1].

The statistics surrounding HIV infection paint a sobering picture of this ongoing pandemic [2]. Since the beginning of the epidemic, 85.6 million people have been infected with HIV worldwide, with 40.4 million deaths attributed to the virus. Currently, 39.0 million people are living with HIV globally, representing approximately 0.7% of adults aged 15-49 years worldwide [3].

In the United States, approximately 1.2 million people had HIV at the end of 2021, with 87% aware of their status [4]. While these numbers remain substantial, there’s encouraging news: the annual number of new diagnoses decreased 7% from 2017 to 2021, indicating progress in prevention efforts [4].

The Oral Cavity as a Window to HIV Progression

Research consistently demonstrates that oral manifestations often serve as early indicators of HIV infection and disease progression [5]. The oral cavity’s unique environment, with its diverse microbial ecosystem and direct connection to both the respiratory and digestive systems, makes it particularly susceptible to the immunosuppressive effects of HIV [6].

Clinical studies have identified numerous oral lesions strongly associated with HIV infection, with prevalence rates varying significantly based on the stage of disease and access to antiretroviral therapy (ART) [7]. The most commonly observed manifestations include oral hairy leukoplakia (97.34% CI), oral candidiasis (99.02% CI), and various forms of periodontal disease [8].

Like what you’re learning?  Download a brochure for our online, postgraduate Oral Pathology and Radiology certificate program.

Infectious Complications

• Bacterial Infections: Research has identified distinct patterns of bacterial infections in HIV-positive patients [9]. Linear gingival erythema, previously known as HIV gingivitis, presents as linear erythema without significant plaque formation. This condition affects a substantial portion of HIV-positive patients and requires targeted treatment approaches combining debridement with systemic antibiotics [9].

More severe is necrotizing ulcerative periodontitis, which affects up to 50% of patients with AIDS [10]. This aggressive condition involves rapid progression, severe pain, halitosis, and significant periodontal and bone loss. The condition’s severity often correlates directly with the patient’s CD4 count, making it an important clinical indicator [10].

• Fungal Manifestations: Oroesophageal candidiasis represents one of the most common opportunistic infections, developing in approximately 90% of HIV patients during the course of their illness [11]. Research shows this condition often serves as an early clinical marker of immune system deterioration and can significantly impact patient quality of life [11].

Cryptococcosis, caused by Cryptococcus neoformans, represents the second most commonly encountered fungal infection after candida in HIV patients, affecting 8.5% of this population [12]. Its disseminated form represents the most common life-threatening fungal infection in HIV-positive individuals [12].

• Viral Complications: Studies reveal that various viral infections manifest differently in HIV-positive patients [13]. Primary HIV infection itself often presents as a mononucleosis-like syndrome with fever, lymphadenopathy, pharyngitis, and characteristic rash patterns [13]. Cytomegalovirus (CMV) infections create oral and esophageal ulcers, representing the second most common cause of esophagitis after Candida in this population [14].

Neoplastic Complications: A Research Focus

Cancer research in HIV patients reveals increased susceptibility to specific malignancies [15]. Kaposi sarcoma, a malignant vascular neoplasm strongly associated with human herpes virus Type 8 (HHV8), commonly manifests in oral tissues [15]. Research indicates this cancer’s oral presentation often precedes systemic involvement, highlighting the importance of thorough oral examinations in HIV-positive patients [15].

Non-Hodgkin’s lymphoma may initially present with oral manifestations, appearing as diffuse induration, nodules, or ulcers in the oral cavity [16]. These findings underscore the critical role of dental professionals in early cancer detection [16].

Diagnostic Advances and Clinical Implications

Modern HIV diagnostic protocols have evolved significantly based on extensive research [17]. The fourth-generation HIV antigen/antibody combination test represents a major advancement, offering >99.7% sensitivity and >99.3% specificity while reducing the “window period” to as little as 10 days [17]. This improvement allows for earlier detection and treatment initiation, directly impacting patient outcomes and transmission prevention [17].

Therapeutic Evolution and Prognosis

Perhaps the most remarkable aspect of HIV research involves the transformation of prognosis [18]. The condition has evolved from having an almost 100% fatality rate to becoming a manageable chronic condition within just 20 years—representing an unprecedented change in medical history [18].

Antiretroviral therapy (ART) now enables HIV-positive patients to achieve undetectable viral loads, effectively eliminating sexual transmission risk [19]. This “undetectable equals untransmittable” concept represents a paradigm shift in both treatment and prevention strategies [19].

Research Implications for Dental Practice

Current research emphasizes the crucial role dental professionals play in HIV care [20]. Oral manifestations often precede systemic symptoms, making dental practitioners potential first-line healthcare providers for diagnosis [20]. Regular oral examinations can detect early signs of immune deterioration, facilitating timely medical referral and treatment adjustment [20].

Furthermore, research demonstrates that proper oral health management significantly impacts overall HIV treatment outcomes [21]. Controlling oral infections reduces inflammatory burden, potentially improving antiretroviral therapy effectiveness [21].

Future Directions

Ongoing research continues exploring HIV prevention strategies, including vaccine development [22]. Recent clinical trials of preventive HIV vaccine candidates, such as VIR-1388, represent promising developments in the field [22]. These vaccines aim to instruct immune systems to produce HIV-recognizing T cells, potentially preventing chronic infection establishment [22].

Conclusion

The relationship between HIV and oral health remains a dynamic field of research with direct clinical implications [23]. As our understanding deepens, dental professionals must stay informed about evolving diagnostic techniques, treatment protocols, and prevention strategies. The oral cavity’s role as both an early indicator of HIV infection and a target for opportunistic infections underscores the critical importance of comprehensive oral healthcare in HIV management [23].

Through continued research and clinical vigilance, we can better serve this vulnerable population while contributing to broader public health goals of HIV prevention and treatment optimization [23].

Postgraduate Oral Pathology and Radiology Certificate

Learn more about the clinical and didactic skills necessary to evaluate and manage patients with oral diseases by enrolling in Herman Ostrow School of USC’s online, competency-based certificate program in Oral Pathology and Radiology.

References

1. Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. The Lancet. 2014;384(9939):258-271.
2. UNAIDS/WHO estimates. Global HIV & AIDS statistics — Fact sheet. UNAIDS. 2023.
3. Joint United Nations Programme on HIV/AIDS. UNAIDS Data 2023. Geneva: UNAIDS; 2023.
4. Centers for Disease Control and Prevention. HIV Surveillance Report, 2021. Vol. 34. Atlanta: US Department of Health and Human Services; 2023.
5. Patton LL. Oral lesions associated with human immunodeficiency virus disease. Dent Clin North Am. 2013;57(4):673-698.
6. Shiboski CH, Patton LL, Webster-Cyriaque JY, et al. The Oral HIV/AIDS Research Alliance: updated case definitions of oral disease endpoints. J Oral Pathol Med. 2009;38(6):481-488.
7. Reznik DA. Oral manifestations of HIV disease. Top HIV Med. 2005;13(5):143-148.
8. Vistoso Monreal A. Global estimate of the prevalence of oral lesions among people with HIV/AIDS using meta-analysis. OFPM #727 Infectious Diseases Manual. USC Ostrow School of Dentistry; 2023.
9. Glick M, Muzyka BC, Salkin LM, Lurie D. Necrotizing ulcerative periodontitis: a marker of immune deterioration and a predictor for the diagnosis of AIDS. J Periodontol. 1994;65(5):393-397.
10. Winkler JR, Murray PA. Periodontal disease in HIV-infected patients. J Periodontol. 1999;70(9):990-995.
11. Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med. 1994;97(4):339-346.
12. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS–100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev. 1995;8(4):515-548.
13. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125(4):257-264.
14. Wilcox CM, Schwartz DA. A pilot study of oral corticosteroid therapy for idiopathic esophageal ulcerations associated with human immunodeficiency virus infection. Am J Med. 1992;93(2):131-134.
15. Epstein JB, Cabay RJ, Glick M. Oral malignancies in HIV disease: changes in disease presentation, increasing understanding of molecular pathogenesis, and current management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(5):571-578.
16. Neville BW, Damm DD, Allen CM, Chi AC. Oral and Maxillofacial Pathology. 4th ed. St. Louis: Elsevier; 2016.
17. Centers for Disease Control and Prevention. Laboratory testing for the diagnosis of HIV infection: updated recommendations. Atlanta: US Department of Health and Human Services; 2014.
18. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853-860.
19. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
20. Patton LL, Phelan JA, Ramos-Gomez FJ, Nittayananta W, Shiboski CH, Mbuguye TL. Prevalence and classification of HIV-associated oral lesions. Oral Dis. 2002;8 Suppl 2:98-109.
21. Shiboski CH, Yao TJ, Russell JS, et al. The association between oral disease and HIV viral load in adults. J Am Dent Assoc. 2019;150(6):509-516.
22. National Institute of Allergy and Infectious Diseases. Clinical trial of HIV vaccine begins in United States and South Africa. NIAID Media Advisory. September 20, 2023.
23. Alard E, Butnariu AB, Grillo M, et al. Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets. Cancers (Basel). 2020;12(7):1826.